News & AnalysisORI Capital wraps up sophomore life sciences fund at $260mORI Fund II will invest in early-stage biotech companies.ByLawrence Aragon andIris Dorbian23 February 2024•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.FundraisingFundraisingBriefs